argenx SE

Equities

ARGX

NL0010832176

Biotechnology & Medical Research

Market Closed - Euronext Bruxelles Other stock markets 16:35:03 28/06/2024 BST			5-day change	1st Jan Change
408.6 ^EUR	-1.87%		+9.90%	+18.95%

06-26	HC Wainwright Raises Argenx's Price Target to $490 From $448, Maintains Buy Rating	MT
06-24	Truist Securities Raises Argenx's Price Target to $480 From $440, Buy Rating Maintained	MT

Argenx : argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting

June 26, 2024 at 10:37 am

argenx SE

argenx SE

Below you will find information from the register publication of inside information. The information has been provided by the organisation.

Registration date25 jun 2024 - 22:42

Statutory nameargenx SE

Titleargenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting

Previous result

Next result

Related downloads

202406250000000022_argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting.pdf(opens in a new window)

Date last update: 26 June 2024

Attachments

Original Link
Permalink

Disclaimer

arGEN-X SE published this content on 25 June 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 June 2024 09:36:38 UTC.

Latest news about argenx SE

HC Wainwright Raises Argenx's Price Target to $490 From $448, Maintains Buy Rating	06-26	MT
Truist Securities Raises Argenx's Price Target to $480 From $440, Buy Rating Maintained	06-24	MT
Scotiabank Raises Argenx's Price Target to $416 From $408, Sector Perform Rating Maintained	06-24	MT
Goldman Sachs Raises Argenx's Price Target to $506 From $484, Buy Rating Maintained	06-24	MT
Citigroup Raises Argenx's Price Target to $512 From $463, Buy Rating Maintained	06-24	MT
European shares start the week higher on autos, banks	06-24	RE
Argenx Shares Rise Following Vyvgart Hytrulo Approval	06-24	MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	06-24	MT
Global markets live: Novo Nordisk, Apple, UPS, Eli Lilly, Qualcomm...	06-24
BofA Securities Raises Argenx Price Target to $607 From $535, Maintains Buy Rating	06-24	MT
Stifel Raises Argenx Price Target to $500 From $485, Maintains Buy Rating	06-24	MT
Sector Update: Health Care Stocks Advance Premarket Monday	06-24	MT
Piper Sandler Adjusts argenx Price Target to $535 From $522, Maintains Overweight Rating	06-24	MT
Wells Fargo Adjusts argenx Price Target to $542 From $478, Maintains Overweight Rating	06-24	MT
Evercore ISI Raises Price Target on argenx to $478 From $437, Keeps Outperform Rating	06-24	MT
Argenx Says FDA Approved Vyvgart Hytrulo for Treatment of Neuromuscular Disorder	06-24	MT
European shares start week on bright footing on autos, banks' boost	06-24	RE
Europe opens hesitant as metal prices fall	06-24	RE
European shares open flat as falling mining stocks curb gains	06-24	RE
Argenx Secures US FDA Approval for Chronic Inflammatory Demyelinating Polyneuropathy Treatment	06-24	MT
Transcript : Argenx SE - Special Call	06-21
Argenx SE Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy	06-21	CI
Argenx Gets FDA Approval for Chronic Inflammatory Demyelinating Polyneuropathy Treatment	06-21	DJ
Wedbush Adjusts Price Target on argenx to $519 From $521, Maintains Outperform Rating	06-17	MT
Pliant Therapeutics, Inc. Appoints Steve Krognes to Its Board of Directors and Chairperson of Audit Committee	06-13	CI

Chart argenx SE

Duration

Period

More charts

Company Profile

argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx SE is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx SE has offices in Belgium, the United States, and Japan.

Sector

Biotechnology & Medical Research

Calendar

16/07/2024 - R&D Day

Related indices

STOXX EUROPE 600 (EUR) , BEL-20

More about the company

Income Statement Evolution

More financial data

Ratings for argenx SE

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

408.6 EUR

Average target price

451.6 EUR

Spread / Average Target

+10.53%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ARGENX SE	+18.95%	26.02B
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	121B
REGENERON PHARMACEUTICALS, INC.	+19.67%	113B
BIONTECH SE	-23.86%	19.39B
GENMAB A/S	-19.03%	15.91B
BEIGENE, LTD.	-20.90%	15.09B
WUXI APPTEC CO., LTD.	-46.14%	15.06B
SAREPTA THERAPEUTICS, INC.	+63.85%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+4.49%	13.85B
INSMED INCORPORATED	+116.20%	10.8B

Bio Therapeutic Drugs